B L Pearse1,2,3,4, I Smith1, D Faulke1, D Wall2, J F Fraser3,5, E G Ryan6,7, L Drake8, I L Rapchuk1, P Tesar2, M Ziegenfuss3,5, Y L Fung4,9. 1. Department of Anesthesia, The Prince Charles Hospital, Brisbane, Qld, Australia. 2. Department of Cardiac Surgery, The Prince Charles Hospital, Brisbane, Qld, Australia. 3. Adult Intensive Care Service, The Prince Charles Hospital, Brisbane, Qld, Australia. 4. Center of Health Practice Innovation, Griffith University, Brisbane, Qld, Australia. 5. Critical Care Research Group, The Prince Charles Hospital, Brisbane, Qld, Australia. 6. School of Mathematical Sciences, Queensland University of Technology, Brisbane, Qld, Australia. 7. Biostatistics Department, King's College London, Denmark Hill, UK. 8. Cardiac Surgery Clinical Information Service, The Prince Charles Hospital, Brisbane, Qld, Australia. 9. Inflammation and Healing Research Cluster, School of Health & Sports Sciences, University of Sunshine Coast, Sunshine Coast, Qld, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Excessive bleeding is a risk associated with cardiac surgery. Treatment invariably requires transfusion of blood products; however, the transfusion itself may contribute to postoperative sequelae. Our objective was to analyse a quality initiative designed to provide an evidenced-based approach to bleeding management. MATERIALS AND METHODS: A retrospective analysis compared blood product transfusion and patient outcomes 15 months before and after implementation of a bleeding management protocol. The protocol incorporated point-of-care coagulation testing (POCCT) with ROTEM and Multiplate to diagnose the cause of bleeding and monitor treatment. RESULTS: Use of the protocol led to decreases in the incidence of transfusion of PRBCs (47·3% vs. 32·4%; P < 0·0001), FFP (26·9% vs. 7·3%; P < 0·0001) and platelets (36·1% vs. 13·5%; P < 0·0001). During the intra-operative period, the percentage of patients receiving cryoprecipitate increased (2·7% vs. 5·1%; P = 0·002), as did the number of units transfused (248 vs. 692; P < 0·0001). The proportion of patients who received tranexamic acid increased (13·7% to 68·2%; P < 0·0001). There were reductions in re-exploration for bleeding (5·6% vs. 3·4; P = 0·01), superficial chest wound (3·3% vs. 1·4%; P = 0·002), leg wound infection (4·6% vs. 2·0%; P < 0·0001) and a 12% reduction in mean length of stay from operation to discharge (95%: 9-16%, P < 0·0001). Acquisition cost of blood products decreased by $1 029 118 in the 15-month period with the protocol. CONCLUSIONS: The implementation of a bleeding management protocol supported by POCCT in a cardiac surgery programme was associated with significant reductions in the transfusion of allogeneic blood products, improved outcomes and reduced cost.
BACKGROUND AND OBJECTIVES:Excessive bleeding is a risk associated with cardiac surgery. Treatment invariably requires transfusion of blood products; however, the transfusion itself may contribute to postoperative sequelae. Our objective was to analyse a quality initiative designed to provide an evidenced-based approach to bleeding management. MATERIALS AND METHODS: A retrospective analysis compared blood product transfusion and patient outcomes 15 months before and after implementation of a bleeding management protocol. The protocol incorporated point-of-care coagulation testing (POCCT) with ROTEM and Multiplate to diagnose the cause of bleeding and monitor treatment. RESULTS: Use of the protocol led to decreases in the incidence of transfusion of PRBCs (47·3% vs. 32·4%; P < 0·0001), FFP (26·9% vs. 7·3%; P < 0·0001) and platelets (36·1% vs. 13·5%; P < 0·0001). During the intra-operative period, the percentage of patients receiving cryoprecipitate increased (2·7% vs. 5·1%; P = 0·002), as did the number of units transfused (248 vs. 692; P < 0·0001). The proportion of patients who received tranexamic acid increased (13·7% to 68·2%; P < 0·0001). There were reductions in re-exploration for bleeding (5·6% vs. 3·4; P = 0·01), superficial chest wound (3·3% vs. 1·4%; P = 0·002), leg wound infection (4·6% vs. 2·0%; P < 0·0001) and a 12% reduction in mean length of stay from operation to discharge (95%: 9-16%, P < 0·0001). Acquisition cost of blood products decreased by $1 029 118 in the 15-month period with the protocol. CONCLUSIONS: The implementation of a bleeding management protocol supported by POCCT in a cardiac surgery programme was associated with significant reductions in the transfusion of allogeneic blood products, improved outcomes and reduced cost.
Authors: Christian Schoergenhofer; Nina Buchtele; Michael Schwameis; Johann Bartko; Bernd Jilma; Petra Jilma-Stohlawetz Journal: Clin Exp Med Date: 2017-02-16 Impact factor: 3.984
Authors: Margaret R Passmore; Yoke L Fung; Gabriela Simonova; Samuel R Foley; Sara D Diab; Kimble R Dunster; Michelle M Spanevello; Charles I McDonald; John-Paul Tung; Natalie M Pecheniuk; Karen Hay; Kiran Shekar; John F Fraser Journal: Crit Care Date: 2017-07-29 Impact factor: 9.097
Authors: Klaus Görlinger; Antonio Pérez-Ferrer; Daniel Dirkmann; Fuat Saner; Marc Maegele; Ángel Augusto Pérez Calatayud; Tae-Yop Kim Journal: Korean J Anesthesiol Date: 2019-05-17
Authors: Bronwyn L Pearse; Samantha Keogh; Claire M Rickard; Daniel J Faulke; Ian Smith; Douglas Wall; Charles McDonald; Yoke L Fung Journal: J Multidiscip Healthc Date: 2020-01-15
Authors: Sebastian Woźniak; Karolina Woźniak; Tomasz Hryniewiecki; Mariusz Kruk; Jacek Różański; Mariusz Kuśmierczyk Journal: Kardiochir Torakochirurgia Pol Date: 2016-03-30